It has been shown that BRCA1-deficient breast cancers exhibit higher abundances of tumor-infiltrating lymphocytes (TILs) and greater enrichment of T cell inflammation signatures than BRCA1-proficient breast cancers, with a wide range of variation20,21. This evidence concerns the gene BRCA1 and breast carcinoma.